By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Acucela Inc. 

1301 Second Avenue
Suite 1900, 19th Floor
Seattle  Washington  98101-3805  U.S.A.
Phone: 206-805-8300 Fax: 206-805-8301


SEARCH JOBS
Acucela Inc. is a clinical-stage biotechnology company focused on leveraging promising science in visual cycle modulation (VCM) to develop new methods for treating blinding eye diseases that affect tens of millions of people worldwide. The company’s orally-delivered VCM therapies, which selectively target cells within the retina to protect visual acuity, have the potential to be used to treat several devastating eye diseases, including dry age-related macular degeneration (AMD), retinopathy of prematurity, Stargardt disease and diabetic retinopathy. Acucela is also developing, with Otsuka Pharmaceutical, Rebamipide ophthalmic suspension, a Phase 3 product candidate for dry eye.

For more information, please visit www.Acucela.com.


Key Statistics


Email: investor@acucela.com
Ownership: Private

Web Site: Acucela
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
Washington State Court Issues Order Requiring Acucela To Hold Special Shareholders Meeting 3/16/2015 1:02:35 PM
Proxy Fight Looms as Acucela Snaps Back at Ousted CEO 3/13/2015 6:06:57 AM
Acucela Files Opposition To SBI/Kubota Motion To Compel Company To Call Special Shareholders Meeting 3/12/2015 10:21:17 AM
Ousted Acucela CEO Continues to Fight Over Board Members and the Biotech's Future 3/10/2015 6:10:03 AM
Acucela Inc. To Hold 2015 Annual Meeting Of Shareholders On June 8, 2015 3/4/2015 11:24:26 AM
Acucela Inc. Received A Request To Hold A Special Meeting Of Shareholders 2/3/2015 12:57:05 PM
Large Acucela Inc. Shareholder Wants to Oust Four Out of Five Board Members 2/3/2015 6:50:48 AM
Acucela Inc. Announces That Brian O’Callaghan Will Assume The Role Of CEO; Ryo Kubota, M.D., Ph.D., To Remain Chairman Of The Board 12/23/2014 8:29:56 AM
Acucela Inc.’s Emixustat Hydrochloride, in Development For Geographic Atrophy Associated With Dry Age-Related Macular Degeneration, Subject Of Podium Presentation At The American Academy of Ophthalmology 2014 Annual Meeting 10/17/2014 10:31:30 AM
Acucela Inc. To Present At The Biocentury Newsmakers In The Biotech Industry Conference 9/18/2014 10:52:59 AM
1234567
//-->